Anti-prion activity of brilliant blue G

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Iwamaru, Yoshifumi ^a   Takenouchi, Takato ^b   Murayama, Yuichi ^a   Okada, Hiroyuki ^a   Imamura, Morikazu ^a   Shimizu, Yoshihisa ^a   Hashimoto, Makoto ^c   Mohri, Shirou ^a   Yokoyama, Takashi ^a   Kitani, Hiroshi ^b  

^a NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^b NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

A 438079; BRILLIANT BLUE; BRILLIANT BLUE G; PRION PROTEIN; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; COOMASSIE BRILLIANT BLUE; FUCHSINE; ISOPROTEIN; PURINERGIC P2X RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BRAIN LEVEL; CELL LOSS; CELLULAR DISTRIBUTION; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE CONTROL; DRUG STRUCTURE; IN VIVO STUDY; MICROGLIA; MOUSE; NERVE CELL; NERVE CELL DEGENERATION; NONHUMAN; PRION; PRION DISEASE; PROTEIN METABOLISM; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; VIRUS INHIBITION; ANIMAL; BIOSYNTHESIS; BRAIN; CELL LINE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; PROTEOSTASIS DEFICIENCY; SCRAPIE;

MUS;

ANIMALS; BRAIN; CELL LINE; DOWN-REGULATION; MICE; MICROGLIA; NEURONS; PRIONS; PROTEIN ISOFORMS; PROTEIN TRANSPORT; PROTEOSTASIS DEFICIENCIES; PURINERGIC P2X RECEPTOR ANTAGONISTS; ROSANILINE DYES; SCRAPIE;

EID: 84861690058     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037896     Document Type: Article

References (63)

1. Prusiner SB, (1991) Molecular biology of prion diseases. Science 252: 1515-1522.
2. Ferrari D, Villalba M, Chiozzi P, Falzoni S, Ricciardi-Castagnoli P, et al. (1996) Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J Immunol 156: 1531-1539.
3. Ballerini P, Rathbone MP, Di Iorio P, Renzetti A, Giuliani P, et al. (1996) Rat astroglial P2Z (P2X7) receptors regulate intracellular calcium and purine release. Neuroreport 7: 2533-2537.
4. Matute C, Torre I, Pérez-Cerdá F, Pérez-Samartín A, Alberdi E, et al. (2007) P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 27: 9525-9533.
5. Deuchars SA, Atkinson L, Brooke RE, Musa H, Milligan CJ, et al. (2001) Neuronal P2X7 receptors are targeted to presynaptic terminals in the central and peripheral nervous systems. J Neurosci 21: 7143-7152.
6. Sperlágh B, Köfalvi A, Deuchars J, Atkinson L, Milligan CJ, et al. (2002) Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. J Neurochem 81: 1196-1211.
7. Marcoli M, Cervetto C, Paluzzi P, Guarnieri S, Alloisio S, et al. (2008) P2X7 pre-synaptic receptors in adult rat cerebrocortical nerve terminals: a role in ATP-induced glutamate release. J Neurochem 105: 2330-2342.
8. Papp L, Vizi ES, Sperlágh B, (2004) Lack of ATP-evoked GABA and glutamate release in the hippocampus of P2X7 receptor-/- mice. Neuroreport 15: 2387-2391.
9. Monif M, Burnstock G, Williams DA, (2010) Microglia: proliferation and activation driven by the P2X7 receptor. Int J Biochem Cell Biol 42: 1753-1756.
10. Ferrari D, Chiozzi P, Falzoni S, Hanau S, Di Virgilio F, (1997) Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med 185: 579-582.
11. Takenouchi T, Sugama S, Iwamaru Y, Hashimoto M, Kitani H, (2009) Modulation of the ATP-lnduced release and processing of IL-1beta in microglial cells. Crit Rev Immunol 29: 335-345.
12. Skaper SD, Facci L, Culbert AA, Evans NA, Chessell I, et al. (2006) P2X(7) receptors on microglial cells mediate injury to cortical neurons in vitro. Glia 54: 234-242.
13. Walter L, Dinh T, Stella N, (2004) ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase. J Neurosci 24: 8068-8074.
14. Witting A, Walter L, Wacker J, Möller T, Stella N, (2004) P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci U S A 101: 3214-3219.
15. Ortega F, Pérez-Sen R, Delicado EG, Teresa Miras-Portugal M, (2011) ERK1/2 activation is involved in the neuroprotective action of P2Y(13) and P2X7 receptors against glutamate excitotoxicity in cerebellar granule neurons. Neuropharmacology.
16. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, et al. (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6: 12.
17. Parvathenani LK, Tertyshnikova S, Greco CR, Roberts SB, Robertson B, et al. (2003) P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem 278: 13309-13317.
18. McLarnon JG, Ryu JK, Walker DG, Choi HB, (2006) Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol 65: 1090-1097.
19. Díaz-Hernández M, Díez-Zaera M, Sánchez-Nogueiro J, Gómez-Villafuertes R, Canals JM, et al. (2009) Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J 23: 1893-1906.
20. Takenouchi T, Iwamaru Y, Imamura M, Kato N, Sugama S, et al. (2007) Prion infection correlates with hypersensitivity of P2X7 nucleotide receptor in a mouse microglial cell line. FEBS Lett 581: 3019-3026.
21. Ryu JK, McLarnon JG, (2008) Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer's disease. Neuroreport 19: 1715-1719.
22. Wang X, Arcuino G, Takano T, Lin J, Peng WG, et al. (2004) P2X7 receptor inhibition improves recovery after spinal cord injury. Nat Med 10: 821-827.
23. Takenouchi T, Sekiyama K, Sekigawa A, Fujita M, Waragai M, et al. (2010) P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz) 58: 91-96.
24. Bolognesi ML, Ai Tran HN, Staderini M, Monaco A, López-Cobeñas A, et al. (2010) Discovery of a class of diketopiperazines as antiprion compounds. ChemMedChem 5: 1324-1334.
25. Caughey B, Race RE, (1992) Potent inhibition of scrapie-associated PrP accumulation by congo red. J Neurochem 59: 768-771.
26. Gilch S, Winklhofer K, Groschup M, Nunziante M, Lucassen R, et al. (2001) Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J 20: 3957-3966.
27. Caughey B, Raymond L, Raymond G, Maxson L, Silveira J, et al. (2003) Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol 77: 5499-5502.
28. Shimizu Y, Kaku-Ushiki Y, Iwamaru Y, Muramoto T, Kitamoto T, et al. (2010) A novel anti-prion protein monoclonal antibody and its single-chain fragment variable derivative with ability to inhibit abnormal prion protein accumulation in cultured cells. Microbiol Immunol 54: 112-121.
29. Iwamaru Y, Shimizu Y, Imamura M, Murayama Y, Endo R, et al. (2008) Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation. J Neurochem 107: 636-646.
30. Iwamaru Y, Takenouchi T, Ogihara K, Hoshino M, Takata M, et al. (2007) Microglial cell line established from prion protein-overexpressing mice is susceptible to various murine prion strains. J Virol 81: 1524-1527.
31. Nagaoka K, Yoshioka M, Shimozaki N, Yamamura T, Murayama Y, et al. (2010) Sensitive detection of scrapie prion protein in soil. Biochem Biophys Res Commun 397: 626-630.
32. Sakaguchi S, Katamine S, Shigematsu K, Nakatani A, Moriuchi R, et al. (1995) Accumulation of proteinase K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt-Jakob disease agent. J Virol 69: 7586-7592.
33. Daude N, Marella M, Chabry J, (2003) Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci 116: 2775-2779.
34. Caughey B, Raymond GJ, (1991) The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 266: 18217-18223.
35. Borchelt DR, Taraboulos A, Prusiner SB, (1992) Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J Biol Chem 267: 16188-16199.
36. Marijanovic Z, Caputo A, Campana V, Zurzolo C, (2009) Identification of an intracellular site of prion conversion. PLoS Pathog 5: e1000426.
37. Goold R, Rabbanian S, Sutton L, Andre R, Arora P, et al. (2011) Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat Commun 2: 281.
38. Yamasaki T, Suzuki A, Shimizu T, Watarai M, Hasebe R, et al. (2012) Characterization of intracellular localization of PrP(Sc) in prion-infected cells using a mAb that recognizes the region consisting of aa 119-127 of mouse PrP. J Gen Virol 93: 668-680.
39. Rambold AS, Miesbauer M, Olschewski D, Seidel R, Riemer C, et al. (2008) Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP. J Neurochem 107: 218-229.
40. Shyng SL, Lehmann S, Moulder KL, Harris DA, (1995) Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J Biol Chem 270: 30221-30229.
41. Murayama Y, Yoshioka M, Yokoyama T, Iwamaru Y, Imamura M, et al. (2007) Efficient in vitro amplification of a mouse-adapted scrapie prion protein. Neurosci Lett 413: 270-273.
42. Jeffrey M, Halliday W, Bell J, Johnston A, MacLeod N, et al. (2000) Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol 26: 41-54.
43. Cunningham C, Deacon R, Wells H, Boche D, Waters S, et al. (2003) Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur J Neurosci 17: 2147-2155.
44. Kordek R, Hainfellner J, Liberski P, Budka H, (1999) Deposition of the prion protein (PrP) during the evolution of experimental Creutzfeldt-Jakob disease. Acta Neuropathol 98: 597-602.
45. Schultz J, Schwarz A, Neidhold S, Burwinkel M, Riemer C, et al. (2004) Role of interleukin-1 in prion disease-associated astrocyte activation. Am J Pathol 165: 671-678.
46. Brown D, (2001) Microglia and prion disease. Microsc Res Tech 54: 71-80.
47. Taraboulos A, Raeber AJ, Borchelt DR, Serban D, Prusiner SB, (1992) Synthesis and trafficking of prion proteins in cultured cells. Mol Biol Cell 3: 851-863.
48. Quaglio E, Chiesa R, Harris D, (2001) Copper converts the cellular prion protein into a protease-resistant species that is distinct from the scrapie isoform. J Biol Chem 276: 11432-11438.
49. Compton SJ, Jones CG, (1985) Mechanism of dye response and interference in the Bradford protein assay. Anal Biochem 151: 369-374.
50. Heiseke A, Aguib Y, Riemer C, Baier M, Schätzl H, (2009) Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. J Neurochem 109: 25-34.
51. Kang SW, Rane NS, Kim SJ, Garrison JL, Taunton J, et al. (2006) Substrate-specific translocational attenuation during ER stress defines a pre-emptive quality control pathway. Cell 127: 999-1013.
52. Cabral GA, Harmon KN, Carlisle SJ, (2001) Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Adv Exp Med Biol 493: 207-214.
53. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88.
54. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, et al. (2004) Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 19: 1691-1698.
55. Dirikoc S, Priola S, Marella M, Zsürger N, Chabry J, (2007) Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci 27: 9537-9544.
56. Brown AR, Webb J, Rebus S, Walker R, Williams A, et al. (2003) Inducible cytokine gene expression in the brain in the ME7/CV mouse model of scrapie is highly restricted, is at a strikingly low level relative to the degree of gliosis and occurs only late in disease. J Gen Virol 84: 2605-2611.
57. Tribouillard-Tanvier D, Striebel J, Peterson K, Chesebro B, (2009) Analysis of protein levels of 24 cytokines in scrapie agent-infected brain and glial cell cultures from mice differing in prion protein expression levels. J Virol 83: 11244-11253.
58. Walsh D, Betmouni S, Perry V, (2001) Absence of detectable IL-1beta production in murine prion disease: a model of chronic neurodegeneration. J Neuropathol Exp Neurol 60: 173-182.
59. Boche D, Cunningham C, Docagne F, Scott H, Perry V, (2006) TGFbeta1 regulates the inflammatory response during chronic neurodegeneration. Neurobiol Dis 22: 638-650.
60. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, et al. (2003) Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 18: 2731-2742.
61. Hracskó Z, Baranyi M, Csölle C, Gölöncsér F, Madarász E, et al. (2011) Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson's disease. Mol Neurodegener 6: 28.
62. Remy M, Thaler S, Schumann RG, May CA, Fiedorowicz M, et al. (2008) An in vivo evaluation of Brilliant Blue G in animals and humans. Br J Ophthalmol 92: 1142-1147.
63. Iriyama A, Kadonosono K, Tamaki Y, Yanagi Y, (2012) Effect of Brilliant Blue G on the retinal ganglion cells of rats. Retina 32: 613-616.